COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN

被引：0
|
作者：
Saiyarsarai, P. [1 ]
Khosroshahi, Ghazizadeh A. [1 ]
Khedmati, J. [1 ]
Ghaffari, S. [2 ]
Soleymani, F. [1 ]
Seyyedifar, M. [3 ]
机构：
[1] Univ Tehran Med Sci, Dept Pharmacoecon & Pharmaceut Adm, Fac Pharm, Tehran 07, Iran
[2] Social Secur Res Inst, Tehran 07, Iran
[3] Univ Tehran Med Sci, Pharmaceut Management & Econ Res Ctr, Tehran, Iran
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB25
引用
收藏
页码：S576 / S576
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China
    James L. Palmer
    Meaghan Gibbs
    Huib WKFH Scheijbeler
    Robert W. Kotchie
    Steffen Nielsen
    Jeremy White
    William J. Valentine
    [J]. Advances in Therapy, 2008, 25 : 752 - 774
  • [22] PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
    Aagren, M.
    Thomsen, T. L.
    Knudsen, V. K.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A10 - A10
  • [23] Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for the treatment of type 2 diabetes in a Spanish setting
    Tucker, D.
    Valentine, W. J.
    Nielsen, S.
    Townsend, C.
    Kotchie, R.
    Scheijbeler, H.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A263 - A263
  • [24] COST-EFFECTIVENESS OF SWITCHING TO BIPHASIC INSULIN ASPART FROM HUMAN PREMIX INSULIN IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xiao, J.
    Bian, X.
    Zhang, Y.
    Yang, L.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A250 - A250
  • [25] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    [J]. VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [26] Efficacy of biphasic insulin aspart in patients with type 2 diabetes
    Halimi, S
    Raskin, P
    Liebl, A
    Kawamori, R
    Fulcher, G
    Yan, G
    [J]. CLINICAL THERAPEUTICS, 2005, 27 : S57 - S74
  • [27] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [28] Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
    Lindholm, A
    Jensen, LB
    Home, PD
    Raskin, P
    Boehm, BO
    Råstam, J
    [J]. DIABETES CARE, 2002, 25 (05) : 876 - 882
  • [29] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [30] Biphasic insulin aspart and biphasic human insulin in type 2 diabetes: A comparison
    Jacobsen, LV
    Bell, PM
    McSorely, P
    Kristensen, A
    [J]. DIABETES, 2000, 49 : A112 - A112
12345